Reliability of the walking energy cost test and the six-minute walk test in boys with Duchenne muscular dystrophy

Neuromuscular Disorders

Volumn 24, Issue 3, 2014, Pages 216-221

  Kempen, J C E ^a   Harlaar, J ^a   van der Kooi, A J ^b   de Groot, I J M ^c   van den Bergen, J C ^d   Niks, E H ^d   Verschuuren, J J G M ^d   Brehm, M A ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Duchenne muscular dystrophy; Energy cost of walking test; Reliability; Six minute walking test; Walking ability

Indexed keywords

DUCHENNE MUSCULAR DYSTROPHY; ENERGY COST OF WALKING TEST; RELIABILITY; SIX MINUTE WALKING TEST; WALKING ABILITY;

CHILD; ENERGY METABOLISM; EXERCISE TEST; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; WALKING;

EID: 84894227183     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2013.11.015     Document Type: Article

References (39)

1. Emery A.E.H. The muscular dystrophies. Lancet 2002, 359(9307):687-695.
2. Hoffman E.P., Bronson A., Levin A.A., et al. Restoring dystrophin expression in Duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. Am J Pathol 2011, 179(1):12-22.
3. Zubrzycka-Gaarn E.E., Bulman D.E., Karpati G., et al. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature 1988, 333(6172):466-469.
4. Moser H. Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention. Hum Genet 1984, 66(1):17-40.
5. Kohler M., Clarenbach C.F., Bahler C., Brack T., Russi E.W., Bloch K.E. Disability and survival in Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatr 2009, 80(3):320-325.
6. Cirak S., Arechavala-Gomeza V., Guglieri M., et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011, 378(9791):595-605.
7. Beytia M.L., Vry J., Kirschner J. Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives. Acta Myol 2012, 31(1):4-8.
8. Goemans N.M., Tulinius M., van den Akker J.T., et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011, 364(16):1513-1522.
9. Brooke M.H., Fenichel G.M., Griggs R.C., et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 1989, 39(4):475-481.
10. McDonald C.M., Abresch R.T., Carter G.T., et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehab 1995, 74(5 Suppl):S70-S92.
11. Boland B.J., Silbert P.L., Groover R.V., Wollan P.C., Silverstein M.D. Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophy. Pediatr Neurol 1996, 14(1):7-12.
12. McDonald C.M., Henricson E.K., Han J.J., et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 2010, 41(4):500-510.
13. Mazzone E., Vasco G., Sormani M.P., et al. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 2011, 77(3):250-256.
14. Bartels B., De Groot J.F., Terwee C.B. The six-minute walk test in chronic pediatric conditions: a systematic review of measurement properties. Phys Ther 2012, 93(4):529-541.
15. De Groot J.F., Takken T. The six-minute walk test in paediatric populations. J Physiother 2011, 57(2):128.
16. Geiger R., Strasak A., Treml B., et al. Six-minute walk test in children and adolescents. J Pediatr 2007, 150(4):395-399.
17. Li A.M., Yin J., Yu C.C.W., et al. The six-minute walk test in healthy children: reliability and validity. Eur Respir J 2005, 25(6):1057-1060.
18. Kierkegaard M., Tollback A. Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy. Neuromuscular Disord 2007, 17(11-12):943-949.
19. Wokke J.H., Escolar D.M., Pestronk A., et al. Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 2008, 38(4):1236-1245.
20. Takeuchi Y., Katsuno M., Banno H., et al. Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve 2008, 38(2):964-971.
21. Flansbjer U.B., Lexell J. Reliability of gait performance tests in individuals with late effects of polio. PM R 2010, 2(2):125-131.
22. McDonald C.M., Henricson E.K., Han J.J., et al. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 2010, 42(6):966-974.
23. Mokkink L.B., Terwee C.B., Gibbons E., et al. Inter-rater agreement and reliability of the COSMIN (COnsensus-based Standards for the selection of health status Measurement Instruments) checklist. BMC Med Res Methodol 2010, 10:82-93.
24. Goemans N., Klingels K., van den Hauwe M., et al. Test-retest reliability and developmental evolution of the 6-minute walk test in Caucasian boys aged 5-12years. Neuromuscular Disord 2013, 23:19-24.
25. Brehm M.A., Becher J., Harlaar J. Reproducibility evaluation of gross and net walking efficiency in children with cerebral palsy. Dev Med Child Neurol 2007, 49(1):45-48.
26. Waters R.L., Mulroy S. The energy expenditure of normal and pathologic gait. Gait Posture 1999, 9(3):207-231.
27. De Groot J.F., Takken T., Schoenmakers M.A.G.C., Tummers L., Vanhees L., Helders P.J.M. Reproducibility of energy cost of locomotion in ambulatory children with spina bifida. Gait Posture 2010, 31(2):159-163.
28. Thomas S.S., Buckon C.E., Schwartz M.H., Russman B.S., Sussman M.D., Aiona M.D. Variability and minimum detectable change for walking energy efficiency variables in children with cerebral palsy. Dev Med Child Neurol 2009, 51(8):615-621.
29. Thomas S.S., Buckon C.E., Schwartz M.H., Sussman M.D., Aiona M.D. Walking energy expenditure in able-bodied individuals: a comparison of common measures of energy efficiency. Gait Posture 2009, 29(4):592-596.
30. Brehm M.A., Harlaar J., Groepenhof H. Validation of the portable VmaxST system for oxygen-uptake measurement. Gait Posture 2004, 20(1):67-73.
31. Robertson R.J., Goss F.L., Boer N.F., et al. Children's OMNI scale of perceived exertion: mixed gender and race validation. Med Sci Sports Exerc 2000, 32(2):452-458.
32. American Thoracic Society Ats statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166(1):111-117.
33. Garby L., Astrup A. The relationship between the respiratory quotient and the energy equivalent of oxygen during simultaneous glucose and lipid oxidation and lipogenesis. Acta Physiol Scand 1987, 129(3):443-444.
34. Brehm M.A., Harlaar J., Schwartz M. Effect of ankle-foot orthoses on walking efficiency and gait in children with cerebral palsy. J Rehabil Med 2008, 40(7):529-534.
35. Lee J., Koh D., Ong C.N. Statistical evaluation of agreement between two methods for measuring a quantitative variable. Comput Biol Med 1989, 19(1):61-70.
36. Brehm M.A., Scholtes V.A., Dallmeijer A.J., Twisk J.W., Harlaar J. The importance of addressing heteroscedasticity in the reliability analysis of ratio-scaled variables: an example based on walking energy-cost measurements. Dev Med Child Neurol 2012, 54(3):267-273.
37. Duffy C.M., Graham H.K., Cosgrove A.P. The influence of ankle-foot orthoses on gait and energy expenditure in spina bifida. J Pediatr Orthop 2000, 20(3):356-361.
38. D'Angelo M.G., Bresolin N. Cognitive impairment in neuromuscular disorders. Muscle Nerve 2006, 34(1):16-33.
39. Schwartz M.H., Koop S.E., Bourke J.L., Baker R. A nondimensional normalization scheme for oxygen utilization data. Gait Posture 2006, 24:14-22.